| 000 | 01625 a2200457 4500 | ||
|---|---|---|---|
| 005 | 20250517175621.0 | ||
| 264 | 0 | _c20180306 | |
| 008 | 201803s 0 0 eng d | ||
| 022 | _a1432-0711 | ||
| 024 | 7 |
_a10.1007/s00404-017-4547-x _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aPan, Jie-Xue | |
| 245 | 0 | 0 |
_aAberrant SERPINE1 DNA methylation is involved in carboplatin induced epithelial-mesenchymal transition in epithelial ovarian cancer. _h[electronic resource] |
| 260 |
_bArchives of gynecology and obstetrics _cDec 2017 |
||
| 300 |
_a1145-1152 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article | ||
| 650 | 0 | 4 | _aAntigens, CD |
| 650 | 0 | 4 | _aAntineoplastic Agents |
| 650 | 0 | 4 |
_aCadherins _xmetabolism |
| 650 | 0 | 4 |
_aCarboplatin _xpharmacology |
| 650 | 0 | 4 | _aCarcinoma, Ovarian Epithelial |
| 650 | 0 | 4 | _aCell Line, Tumor |
| 650 | 0 | 4 | _aDNA Methylation |
| 650 | 0 | 4 | _aDrug Resistance, Neoplasm |
| 650 | 0 | 4 |
_aEpithelial-Mesenchymal Transition _xdrug effects |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aNeoplasms, Glandular and Epithelial _xdrug therapy |
| 650 | 0 | 4 |
_aOvarian Neoplasms _xdrug therapy |
| 650 | 0 | 4 |
_aPlasminogen Activator Inhibitor 1 _xgenetics |
| 650 | 0 | 4 | _aPromoter Regions, Genetic |
| 650 | 0 | 4 | _aSerpin E2 |
| 700 | 1 | _aQu, Fan | |
| 700 | 1 | _aWang, Fang-Fang | |
| 700 | 1 | _aXu, Jian | |
| 700 | 1 | _aMu, Liang-Shan | |
| 700 | 1 | _aYe, Long-Yun | |
| 700 | 1 | _aLi, Jun-Jian | |
| 773 | 0 |
_tArchives of gynecology and obstetrics _gvol. 296 _gno. 6 _gp. 1145-1152 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1007/s00404-017-4547-x _zAvailable from publisher's website |
| 999 |
_c27628993 _d27628993 |
||